TP53 and non-small cell lung carcinoma: In conclusion, our study shows that the combination of EGFR-TKIs and pemetrexed based chemotherapy could significantly improve the ORR and TTP of advanced NSCLC patients with an EGFR/TP53 co-mutation compared with EGFR-TKI monotherapy.